利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.041 秒)

    Eucaryotic expression system
    1.
    发明授权
    Eucaryotic expression system 失效
    真核表达系统

    公开(公告)号：US4912040A

    公开(公告)日：1990-03-27

    申请号：US10351

    申请日：1987-02-03

    申请人： Randal J. Kaufman ,  Andrew Dorner

    发明人： Randal J. Kaufman ,  Andrew Dorner

    IPC分类号： C07K14/705 ,  C12N5/02 ,  C12N5/10 ,  C12N9/72 ,  C12N15/09 ,  C12N15/85 ,  C12P21/00 ,  C12R1/91

    CPC分类号： C12N15/85 ,  C07K14/705 ,  C12N9/6459 ,  C12Y304/21069

    摘要： This invention provides vectors, improved host cells and improved methods for producing a heterologous protein by culturing an improved eucaryotic host cell of this invention transformed or transfected with a vector capable of directing the expression of the heterologous protein. The preferred improved host cell of this invention is a mammalian host cell containing and capable of expressing an anti-sense GRP78 DNA sequence.

    摘要翻译： 本发明提供载体，改良的宿主细胞和通过培养用能够引导异源蛋白质的表达转化或转染的本发明的改良的真核宿主细胞产生异源蛋白质的改进方法。 本发明优选的改良宿主细胞是含有并能够表达反义GRP78 DNA序列的哺乳动物宿主细胞。

    CELL-BASED METHODS FOR DETECTING AND/OR MEASURING BMP-12-RELATED PROTEIN ACTIVITY
    2.
    发明申请
    CELL-BASED METHODS FOR DETECTING AND/OR MEASURING BMP-12-RELATED PROTEIN ACTIVITY 审中-公开
    用于检测和/或测量BMP-12相关蛋白活性的基于细胞的方法

    公开(公告)号：US20090220983A1

    公开(公告)日：2009-09-03

    申请号：US12393628

    申请日：2009-02-26

    申请人： Joanne Archambault ,  Stephen Berasi ,  Andrew Dorner ,  Scott Jelinsky

    发明人： Joanne Archambault ,  Stephen Berasi ,  Andrew Dorner ,  Scott Jelinsky

    IPC分类号： C12Q1/68 ,  C12Q1/02 ,  G01N33/567 ,  G01N33/573

    CPC分类号： C12Q1/6886 ,  C12Q2600/158

    摘要： The invention provides cell-based methods to detect and/or measure the BMP-12-related protein activity of a sample containing a BMP-12-related protein. The methods involve contacting a suitable cell with the sample, and measuring the expression level of at least one BMP-12-related-activity-marker. A dose-dependent increase(s) in the level(s) of the BMP-12-related-activity-markers is indicative of the BMP-12-related protein activity in the sample. The levels of the BMP-12-related-activity-markers of the invention exhibit a dose-responsive increase in response to known BMP-12-related proteins BMP-12, BMP-13, and MP-52, but not to the osteogenic protein, BMP-2.

    摘要翻译： 本发明提供用于检测和/或测量含有BMP-12相关蛋白的样品的BMP-12相关蛋白活性的基于细胞的方法。 所述方法包括使合适的细胞与样品接触，并测量至少一种BMP-12相关活性标记物的表达水平。 BMP-12相关活性标志物水平的剂量依赖性增加指示样品中BMP-12相关的蛋白质活性。 本发明的BMP-12相关活性标志物的水平对已知的BMP-12相关蛋白BMP-12，BMP-13和MP-52的响应性呈现剂量响应性增加，但对成骨 蛋白质，BMP-2。

    Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
    4.
    发明申请
    Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases 审中-公开
    外周血单核细胞对炎症性肠病的表达谱

    公开(公告)号：US20070020660A1

    公开(公告)日：2007-01-25

    申请号：US11448611

    申请日：2006-06-06

    申请人： Michael Burczynski ,  Ron Peterson ,  Natalie Twine ,  Andrew Strahs ,  Frederick Immermann ,  Ullrich Schwertschlag ,  Monette Cotreau ,  Andrew Dorner

    发明人： Michael Burczynski ,  Ron Peterson ,  Natalie Twine ,  Andrew Strahs ,  Frederick Immermann ,  Ullrich Schwertschlag ,  Monette Cotreau ,  Andrew Dorner

    IPC分类号： C12Q1/68 ,  C12P19/34

    CPC分类号： C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158

    摘要： The present invention is directed to the identification of PBMC- and IBD-associated biomarkers that may be used to diagnose inflammatory bowel disease, and optionally, distinguish between PBMCs isolated from a patient with Crohn's disease and PBMCs isolated from a patient with ulcerative colitis. The present invention is further directed to methods of screening, including high throughput methods of screening, for regulatory agents capable of regulating the activity of PBMC- and IBD-associated biomarkers. Provided are compositions of PBMC- and IBD-associated biomarkers, including regulatory agents of at least one PBMC- and IBD-associated biomarker for methods of diagnosis, prognosis, therapeutic intervention and prevention of an inflammatory bowel disease, e.g., Crohn's disease and ulcerative colitis. Moreover, the present invention is also directed to methods that can be used to assess the efficacy of test compounds and therapies in the treatment inflammatory bowel disease, i.e., Crohn's disease or ulcerative colitis.

    摘要翻译： 本发明涉及可用于诊断炎症性肠病的PBMC-和IBD相关生物标志物的鉴定，以及任选地区分从患有克罗恩病的患者和从具有溃疡性结肠炎的患者分离的PBMC中分离的PBMC。 本发明还涉及对能够调节PBMC-和IBD相关生物标志物的活性的调节剂的筛选方法，包括筛选的高通量方法。 提供了PBMC-和IBD相关生物标志物的组合物，包括用于诊断，预后，治疗性干预和预防炎症性肠病的方法的至少一种PBMC和IBD相关生物标志物的调节剂，例如克罗恩病和溃疡性结肠炎 。 此外，本发明还涉及可用于评估测试化合物和疗法在治疗炎性肠病，即克罗恩病或溃疡性结肠炎中的功效的方法。

    Methods and systems for prognosis and treatment of solid tumors
    10.
    发明申请
    Methods and systems for prognosis and treatment of solid tumors 审中-公开
    实体瘤预后与治疗方法与系统

    公开(公告)号：US20060134671A1

    公开(公告)日：2006-06-22

    申请号：US11285502

    申请日：2005-11-22

    申请人： Michael Burczynski ,  Andrew Dorner ,  Natalie Twine ,  William Trepicchio ,  Donna Slonim ,  Andrew Strahs ,  Frederick Immermann

    发明人： Michael Burczynski ,  Andrew Dorner ,  Natalie Twine ,  William Trepicchio ,  Donna Slonim ,  Andrew Strahs ,  Frederick Immermann

    IPC分类号： C12Q1/68 ,  G06F19/00

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

    摘要： The present invention provides methods, systems and equipment for the prognosis and treatment of renal cell carcinoma (RCC) or other solid tumors. Genes prognostic of clinical outcomes of a solid tumor can be identified according to the present invention. The expression profiles of these genes in peripheral blood mononuclear cells (PBMCs) of patients who have the solid tumor are correlated with clinical outcome of these patients. Examples of RCC prognosis genes are illustrated in Tables 2 and 3. These genes can be used as surrogate markers for predicting clinical outcome of an RCC patient of interest. These genes can also be used for the selection of a favorable treatment for an RCC patient of interest.

    摘要翻译： 本发明提供了用于预后和治疗肾细胞癌（RCC）或其他实体瘤的方法，系统和设备。 可以根据本发明鉴定实体瘤的临床结果的基因预后。 这些基因在具有实体瘤的患者的外周血单核细胞（PBMC）中的表达谱与这些患者的临床结果相关。 RCC预后基因的实例如表2和3所示。这些基因可用作预测感兴趣的RCC患者的临床结果的替代标志物。 这些基因也可用于选择感兴趣的RCC患者的有利治疗。